SZSameer M. Zuberi

Sameer M. Zuberi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sameer M. Zuberi has a total of 314 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Etiology‐specific spectrum of epilepsy syndromes (ESSES): Widening the concept of etiology‐specific epilepsies—Report from the ILAE 2021–2025 Terminology Commission

    by Ingrid E. Scheffer, Stéphane Auvin, Francesca Bisulli, Scott Demarest, Elena Gardella, Angelina Kakooza Mwesige, Rima Nabbout, Alshimaa S. Othman, Kollencheri Puthenveettil Vinayan, Robyn Whitney, et al.

    A new type of epilepsy syndrome, an etiology‐specific epilepsy syndrome, was defined in 2022 in recognition of major advances in identifying the many genetic and acquired etiologies underlying the epilepsies. An etiology‐specific epilepsy syndrome refers to where a known etiology is associated with a distinctive epilepsy presentation, including age at seizure onset, seizure types, and other morbidities, such as learning difficulties or intellectual disability, psychiatric features, gut and musculoskeletal problems. However, as we understand more about a specific etiology, such as a gene, it is clear that many etiologies are associated not just with one epilepsy syndrome, but with a range of epilepsy syndromes. Different epilepsy syndromes due to an abnormality in the same gene may reflect different types of dysfunction caused by the specific pathogenic genetic variant. Here, we expand the concept because—knowing the genetic etiology is not enough to ensure optimal clinical care—it requires a more nuanced approach to ensure the patient is managed appropriately. We define the concept of an etiology‐specific spectrum of epilepsy syndromes (ESSES), which incorporates understanding the range of epilepsy syndromes that may be associated with a specific etiology. In some cases, a genetic etiology may be associated with a functional spectrum, such as pathogenic variants in an ion channel subunit that cause loss‐of‐function, gain‐of‐function, or mixed functional effects, each associated with specific epilepsy syndromes that may require different treatment approaches. With other genes, the functional effect may not yet be known, but their spectrum of epilepsy syndromes may be well established through genotype–phenotype studies. The concept of ESSES has the flexibility to grow in its scope with new insights gained from understanding the breadth of epilepsy syndromes associated with a specific etiology and the associated functional impact.

  • Open Access

    How should etiology change the classification of the epilepsies? Report from the ILAE 2021–2025 Terminology Commission

    by Nicola Specchio, Stéphane Auvin, Francesca Bisulli, Scott Demarest, Elena Gardella, Angelina Kakooza Mwesige, Rima Nabbout, Alshimaa S. Othman, Kollencheri Puthenveettil Vinayan, Robyn Whitney, et al.

    The classification of the epilepsies has traditionally relied on clinical and electroencephalographic features. However, advancements in molecular genetics, neuroimaging, and our understanding of epilepsy pathophysiology necessitate a shift toward an etiology‐based approach. Etiology‐specific classification enables precision diagnosis and precision management by integrating genetic, structural, metabolic, infection, and immune‐related insights. Genetic advances have identified more than 1000 epilepsy‐related genes, revealing how variations in a single gene can produce diverse phenotypes and syndromes. Similarly, neuroimaging innovations, such as high‐resolution magnetic resonance imaging and functional imaging, have enhanced detection of subtle structural abnormalities and epileptogenic zones. In 2022, the International League Against Epilepsy introduced the concept of etiology‐specific epilepsy syndromes, emphasizing the interplay between etiology and syndrome. This paradigm shift moves beyond traditional classifications, offering tailored treatments that address seizures and comorbidities to improve prognosis and quality of life. Despite this progress, challenges persist. These include the complexity of defining genotype–phenotype functional relationships, limitations in diagnostic accessibility in resource‐limited settings, and the integration of multifactorial causes. This article proposes extending the concept of etiology‐specific epilepsy syndromes to encompass broader spectrums of phenotypes within each etiology, supported by detailed frameworks for analyzing clinical, imaging, genetic, and functional data. The aim is to refine the classification system to guide personalized, evidence‐based care. This etiology–syndromic spectrum model underscores the importance of lifelong, multidisciplinary approaches to epilepsy management, balancing the value of syndrome‐based insights with the transformative potential of precision medicine.

  • Open Access

    Changes in effectiveness and safety in patients with Lennox–Gastaut syndrome transitioning from the fenfluramine randomized controlled trial to open‐label extension study

    by Rima Nabbout, Orrin Devinsky, Lieven Lagae, Ingrid E. Scheffer, Renzo Guerrini, Joseph Sullivan, Antonio Gil‐Nagel, Sameer M. Zuberi, Kate Riney, Patrick Healy, et al.

    In the phase 3 randomized controlled trial (RCT; NCT03355209) of fenfluramine in Lennox–Gastaut syndrome (LGS), patients in fenfluramine treatment groups (0.2 mg/kg/day, 0.7 mg/kg/day) experienced greater reduction from baseline in frequency of seizures associated with a fall versus placebo, which was sustained in the open‐label extension (OLE) study (NCT03355209). In this post hoc analysis, trajectories of fenfluramine effectiveness and safety, along with dose changes over time, are described for patients with LGS randomized to placebo in RCT who switched to fenfluramine in OLE (PBO‐FFA) and those who received fenfluramine in both RCT/OLE (FFA‐FFA). Among patients who completed 12 months in OLE ( N = 151), numerical improvements in effectiveness outcomes were seen in the PBO‐FFA group ( n = 59) after initiating fenfluramine and were similar to those in the FFA‐FFA group ( n = 92). Regression to the mean was not observed in the PBO‐FFA group, suggesting that changes were due to fenfluramine. Incidence of the most commonly reported treatment‐emergent adverse events increased in the PBO‐FFA group after fenfluramine initiation but decreased in the FFA‐FFA group in OLE. These data demonstrate rapid improvement in seizure frequency and global functioning in both groups with continued clinical improvement as the mean fenfluramine dose was increased. These results confirm that sustained fenfluramine treatment is effective and tolerable. Plain Language Summary: This study assessed the change over time in the number of seizures, overall improvement, and side effects in patients with LGS receiving placebo (no active medicine) or fenfluramine in a 14‐week study; all patients later received fenfluramine in the extension study. Overall, the number of seizures (associated with a fall) decreased once patients initially receiving placebo changed to fenfluramine (optimal effect around Month 4 while receiving a higher dose), but as expected, common side effects were reported more frequently once patients began fenfluramine treatment. Patients, parents, and doctors should be aware of this time course to allow fenfluramine enough time to work.

  • Open Access

    Elicited Repetitive Daily Blindness Associated With Gain-of-Function SCN1A Variants and Responsiveness to Sodium Channel Blockers

    by Sandrine Cestèle, Alexander James Harper, Sebastian Marra, Nathalie Leroudier, Raffaella Rusconi, Sandra Dhifallah, Iain A. Horrocks, Fenella Jane Kirkham, Iona Margaret Rose Morgan, Jaspal Singh, et al.

    Background and ObjectivesElicited Repetitive Daily Blindness (ERDB) is a debilitating condition resulting in recurrent, daily episodes of reversible visual loss. ERDB has been described in individu...


  • Open Access

    Transition from paediatric to adult care in paediatric-onset neurological disorders in Europe: A survey and scoping review

    by Dana Craiu, Maria T. Papadopoulou, Jasna Orazem Mrak, Tita Butenko, Anni Saarela, Cristina Cazacu, Niculae Raluca, Esra Serdaroglu, Masa Malenica, Federico Vigevano, et al.


  • Open Access

    Characterizing early behavioral and social–emotional problems in young children with SCN1A + Dravet syndrome: Findings from the ENVISION prospective natural history study

    by Ingrid E. Scheffer, M. Scott Perry, Joseph Sullivan, Susana Boronat, James Wheless, Andreas Brunklaus, Linda Laux, Anup D. Patel, Colin Roberts, Dennis Dlugos, et al.

    Objective: Dravet syndrome (DS) is the prototypic developmental and epileptic encephalopathy, characterized by drug‐resistant seizures, developmental slowing, and many other morbidities. Detailed characterization of behavioral phenotypes and social–emotional skill development are limited. Methods: We prospectively assessed behavioral and social–emotional problems in the ENVISION natural history study (NCT04537832) of children with DS associated with SCN1A pathogenic variants ( SCN1A + DS) enrolled at p = .002). SDQ Hyperactivity scores worsened over time ( p = .013), whereas emotional difficulties remained stable. VABS‐3 Socialization domain scores, which were already more than 1 SD below the normative mean at baseline, decreased further, particularly in younger participants. Correlation analyses showed that poorer communication abilities were associated with increased problematic behaviors ( R = −.55 for CBCL Total Problems and VABS‐3 Communication scores). Mixed‐effects modeling identified age as the strongest predictor of worsening behavioral outcomes. Significance: We found that behavioral and social–emotional problems are inherent components of DS that present in toddlerhood and worsen throughout early childhood. This highlights the need to diagnose and manage these issues early. Targeted therapy may alleviate the wide‐ranging morbidities that are intrinsic to DS, including the social–emotional and behavior problems that frequently emerge.


  • Open Access

    Cognitive stagnation and executive function deficits in young children with SCN1A + Dravet syndrome: Detailed characterization of onset, progression, and impact in the ENVISION natural history study

    by Joseph Sullivan, M. Scott Perry, Ingrid E. Scheffer, James Wheless, Susana Boronat, Andreas Brunklaus, Linda Laux, Anup D. Patel, Colin Roberts, Dennis Dlugos, et al.

    Objective: Dravet syndrome (DS) is a developmental and epileptic encephalopathy characterized by drug‐resistant seizures and developmental slowing. Although cognitive and executive function deficits have been described, their early trajectory is not well understood. Methods: The prospective ENVISION natural history study (NCT04537832) assessed cognitive, executive, and adaptive function in children younger than 5 years of age with SCN1A + DS every 6 months for up to 2 years using Bayley Scales of Infant and Toddler Development, 3rd Edition (BSID‐III), Wechsler Preschool & Primary Scale of Intelligence, 4th Edition (WPPSI‐IV), Vineland Adaptive Behavior Scales, 3rd Edition (VABS‐3), Behavior Rating Inventory of Executive Function – Preschool Version (BRIEF‐P), and Pediatric Evaluation of Disability Inventory (PEDI). Results: Fifty‐eight children were enrolled, with 47% younger than age 2 years. At least 80% of children did not achieve age‐appropriate milestones. Mean BSID‐III Cognitive raw scores increased minimally, with age‐equivalent gains of only 3 months over 1.5 years. Mean Cognitive Composite scores declined significantly by Month 12 (from 81.6 to 72.2; change: –11.0, 95% confidence interval [CI]: −15.3 to −6.8), signaling a widening gap compared with neurotypical development. Executive function worsened, with mean BRIEF‐P Global Executive Composite T‐scores increasing by 3.2 points/year. For some participants, scores were 5 standard deviations (SD) above the normative mean, reflecting abilities profoundly below age expectations (bottom .00003% of the population). Adaptive functioning worsened, with mean VABS‐3 Adaptive Behavior Composite decreasing from 78.7 to 68.1 over 1.5 years (change: –9.0, 95% CI: −11.9 to −6.1) and greater decline among children 3 years could not remove clothing independently; and when placed on a toilet, 48% could not use it. Significance: Infants and young children with SCN1A + DS show significant and progressive developmental slowing across several domains, highlighting urgent need for therapies to mitigate the devastating impact on individuals and families.


  • Open Access

    Clinically Meaningful Reduction in Drop Seizures in Patients with Lennox–Gastaut Syndrome Treated with Cannabidiol: Post Hoc Analysis of Phase 3 Clinical Trials

    by Nicola Specchio, Stéphane Auvin, Teresa Greco, Lieven Lagae, Charlotte Nortvedt, Sameer M. Zuberi

    Background and Objective In clinical trials of patients with Lennox–Gastaut syndrome (LGS), a ≥ 50% reduction in drop seizure frequency is generally accepted as a key endpoint. However, smaller reductions (< 50%) may yet be impactful for patients in real-world settings. This exploratory analysis evaluated the threshold for a clinically important response in drop seizures that is associated with the Caregiver Global Impression of Change (CGIC) scale score in patients with LGS treated with cannabidiol (CBD) oral solution and assessed the suitability of CGIC as an anchor for meaningful change. Methods This exploratory post hoc analysis included patients with LGS (N = 215, age 2–55 years) receiving CBD (Epidiolex® [USA]/Epidyolex® [EU]; 100 mg/mL oral solution) in two phase 3 randomized placebo-controlled trials (NCT02224690, April–October 2015, and NCT02224560, June– December 2015). Reduction in drop seizures (involving sudden loss of muscle tone) was anchored to CGIC scores of “slightly improved” or better or “much improved” or better, to determine the threshold at which seizure reduction can be considered clinically meaningful to patients. Spearman’s correlation indicated suitability of anchors (absolute value ≥ 0.30 deemed appropriate). Results In the 215 patients receiving CBD with a CGIC score recorded, CGIC was “slightly improved” or better in 60% of patients, and “much improved” or better in 31% after 14 weeks of treatment. With a CGIC rating of “slightly improved” or better, the best threshold for a clinically important response in drop seizure reduction was − 30.6% (57.7% of patients). Mean and median percentage reductions in drop seizures were − 46.9% and − 58.6%, respectively. Using “much improved” or better, the best threshold was − 49.6% (40.5% of patients). Mean and median percentage reductions in drop seizures were − 57.6% and − 66.0%, respectively. Spearman’s correlation was 0.47. Conclusion Anchoring to CGIC of “slightly improved” or better, the threshold for a clinically meaningful reduction in drop seizure frequency was 31%, suggesting that a 50% cutoff may overlook patients with meaningful improvements in their overall condition, as perceived by their caregivers. CGIC scores, although potentially less nuanced than other standardized clinical assessments, were appropriate anchors to determine thresholds. This exploratory analysis may help contextualize clinical trial data to better understand potential patient benefit attained by reductions in drop seizure frequency observed in real-world settings that are < 50%. Clinical Trials Registration Numbers NCT02224560 and NCT02224690. Graphical Abstract


  • Open Access

    Trauma, coping, and adjustment when parenting a child with Dravet syndrome

    by Anthony Mercier, Liam Dorris, Andreas Brunklaus, Joseph D. Symonds, Sameer M. Zuberi, Teresa Finch, Galia Wilson, Claire Eldred


  • Open Access

    POLR3B is associated with a developmental and epileptic encephalopathy with myoclonic‐atonic seizures and ataxia

    by Joseph D. Symonds, Kristen L. Park, Cyril Mignot, Stewart Macleod, Martin Armstrong, Houman Ashrafian, Geneviève Bernard, Kathleen Brown, Andreas Brunklaus, Mary Callaghan, et al.

    Objective: POLR3B encodes the second largest subunit of RNA polymerase III, which is essential for transcription of small non‐coding RNAs. Biallelic pathogenic variants in POLR3B are associated with an inherited hypomyelinating leukodystrophy. Recently, de novo heterozygous variants in POLR3B were reported in six individuals with ataxia, spasticity, and demyelinating peripheral neuropathy. Three of these individuals had epileptic seizures.The aim of this article is to precisely define the epilepsy phenotype associated with de novo heterozygous POLR3B variants.Methods: We used online gene‐matching tools to identify 13 patients with de novo POLR3B variants. We systematically collected genotype and phenotype data from clinicians using two standardized proformas.Results: All 13 patients had novel POLR3B variants. Twelve of 13 variants were classified as pathogenic or likely pathogenic as per American College of Medical Genetics (ACMG) criteria. Patients presented with generalized myoclonic, myoclonic‐atonic, atypical absence, or tonic‐clonic seizures between the ages of six months and 4 years. Epilepsy was classified as epilepsy with myoclonic‐atonic seizures (EMAtS) in seven patients and “probable EMAtS” in two more.Seizures were treatment resistant in all cases. Three patients became seizure‐free. All patients had some degree of developmental delay or intellectual disability. In most cases developmental delay was apparent before the onset of seizures. Three of 13 cases were reported to have developmental stagnation or regression in association with seizure onset.Treatments for epilepsy that were reported by clinicians to be effective were: sodium valproate, which was effective in five of nine patients (5/9) who tried it; rufinamide (2/3); and ketogenic diet (2/3).Additional features were ataxia/incoordination (8/13); microcephaly (7/13); peripheral neuropathy (4/13), and spasticity/hypertonia (6/13).Significance: POLR3B is a novel genetic developmental and epileptic encephalopathy (DEE) in which EMAtS is the predominant epilepsy phenotype. Ataxia, neuropathy, and hypertonia may be variously observed in these patients.